| h-ca6480add4 | Physiological SCFAs may confer indirect anti-synuclein benefit through an entero | 0.67 | 0.60 | FFAR2/FFAR3/GLP1R | proposed | 2026-04-25 | SDA-2026-04-25-gapdebate-18cce7b525 |
| h-c9b96e0e3b | Rab12 may better report chronic lysosomal stress biology than Rab10 in G2019S co | 0.67 | 0.72 | RAB12 | proposed | 2026-04-25 | SDA-2026-04-25-gapdebate-9180363b7c |
| h-8af27bf934 | LPS-primed microglial trained immunity establishes persistent H3K4me3 landscapes | 0.67 | 0.72 | NLRP3, H3K4me3 writers (MLL3/4, SETD1A), H3K27ac (EP300/CREB | proposed | 2026-04-22 | SDA-2026-04-02-gap-synaptic-pruning-microglia |
| h-79a0d74450 | H1: TET-Mediated 5-Hydroxymethylcytosine Loss Drives Neuronal Transcriptomic Dri | 0.67 | 0.72 | TET1, TET2, 5-hydroxymethylcytosine (5hmC) | proposed | 2026-04-22 | SDA-2026-04-04-gap-20260404-120802 |
| h-45bc32028c | Restore AQP4 Perivascular Polarization by Stabilizing DAPC/SNTA1/DAG1 Anchoring | 0.67 | 0.72 | AQP4, SNTA1, DAG1 | proposed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-041445-7e1dc0b2 |
| h-080e9babfd | AQP4-Dependent Astrocyte Swelling Exacerbates Excitotoxic Neuronal Death via Dys | 0.67 | 0.72 | AQP4; SLC1A2 (GLT-1) | proposed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-041445-ce0abc1e |
| h-bc161bb779 | OPTN/TBK1 mutations create selective vulnerability by blocking PINK1-Parkin-inde | 0.67 | 0.70 | OPTN | proposed | 2026-04-21 | SDA-2026-04-08-gap-pubmed-20260406-062212-6777e5dd |
| h-ded1734f | Dissociating SCFA's Dual Signaling Through GPR43/GPR41 Biased Agonism | 0.67 | 0.72 | FFAR2, FFAR3, NLRP3 | promoted | 2026-04-13 | SDA-2026-04-12-gap-debate-20260410-113021-6fbc6da4 |
| h-76ea1f28 | TREM2 R47H Metabolic Lock-in at Cholesterol Ester Accumulation | 0.67 | 0.82 | TREM2/ACAT1/LXR | promoted | 2026-04-16 | SDA-2026-04-15-gap-debate-20260410-112522-57d1cc4f |
| h-a4e259e0 | Enhancing Vagal Cholinergic Signaling to Restore Gut-Brain Anti-Inflammatory Com | 0.67 | 0.50 | CHRNA7 | proposed | 2026-04-03 | SDA-2026-04-01-gap-20260401-225149 |
| h-immunity-c3bc272f | C1q-TREM2 Competition for Phosphatidylserine as Pruning Checkpoint | 0.67 | 0.68 | C1QA, C1QB, TREM2, PSR | open | 2026-04-24 | |
| h-seaad-v4-29e81bbc | Astrocyte MCT1/MCT4 Ratio Disruption with Metabolic Uncoupling | 0.67 | 0.50 | SLC16A1 | debated | 2026-04-03 | SDA-2026-04-03-gap-seaad-v4-20260402065846 |
| h-23b94ed8 | Locus Coeruleus-Hippocampal Circuit Protection | 0.67 | 0.70 | MAPT | promoted | 2026-04-04 | SDA-2026-04-03-26abc5e5f9f2 |
| h-fee0ce2ca5 | TREM2 Agonism Has Narrow Early-Window at DAM1→DAM2 Transition Checkpoint | 0.67 | 0.60 | TREM2, SYK signaling axis | proposed | 2026-04-22 | SDA-2026-04-06-gap-debate-20260406-062045-7a6cf14e |
| h-077e448d | LXRβ-Selective Agonism to Simultaneously Enhance APOE Lipidation and Reduce Micr | 0.67 | 0.70 | LXRβ (NR1H2) | proposed | 2026-04-26 | SDA-2026-04-16-frontier-lipidomics-dcdbc360 |
| h-9eae33ba | Aquaporin-4 Polarization Enhancement via TREK-1 Channel Modulation | 0.67 | 0.30 | KCNK2 | debated | 2026-04-02 | sda-2026-04-01-gap-v2-ee5a5023 |
| h-0791836f | Mitochondrial-Lysosomal Contact Site Engineering | 0.67 | 0.68 | RAB7A | debated | 2026-04-02 | sda-2026-04-01-gap-011 |
| h-c5698ce3 | White Matter Vulnerability Prevention via Oligodendrocyte Protection | 0.67 | 0.75 | CXCL10 | promoted | 2026-04-04 | SDA-2026-04-03-gap-aging-mouse-brain-v3-20260402 |
| h-var-e0e82ff2e2 | TREM2-Mediated Cholesterol Dysregulation in Microglial Senescence | 0.67 | 0.72 | CYP46A1 | promoted | 2026-04-07 | SDA-2026-04-03-gap-aging-mouse-brain-v3-20260402 |
| h-7d4a24d3 | Lipid Droplet Dynamics as Phenotype Switches | 0.67 | 0.35 | DGAT1 and SOAT1 | debated | 2026-04-02 | sda-2026-04-01-gap-007 |
| h-155f0b0c | LRRK2 Volume Sensor Hijacking Drives Metabolic Dysregulation via SIRT1/PGC1α Sup | 0.67 | 0.42 | LRRK2 | proposed | 2026-04-16 | SDA-2026-04-16-gap-pubmed-20260410-170027-a1e5f867 |
| h-var-6a0893ffb6 | Glymphatic-Cholinergic Tau Clearance Cascade | 0.67 | 0.65 | MAPT | proposed | 2026-04-07 | SDA-2026-04-03-26abc5e5f9f2 |
| h-6ce4884a | GAP43-mediated tunneling nanotube stabilization enhances neuroprotective mitocho | 0.67 | 0.35 | GAP43 | debated | 2026-04-02 | sda-2026-04-01-gap-v2-89432b95 |
| h-SDA-2026-04-26-gap | Age-Stratified Dosing Protocol Reflecting Endogenous Decline | 0.67 | 0.43 | AANAT; ASMT; MT1/MT2 | proposed | 2026-04-26 | SDA-2026-04-26-gap-pubmed-20260411-090734-1be1b913 |
| h-SDA-2026-04-26-gap | CSF/Serum NfL Ratio Discriminates Active Transcytosis from Passive BBB Breakdown | 0.67 | 0.44 | NEFL, CAV1 | proposed | 2026-04-26 | SDA-2026-04-26-gap-20260426-002803 |
| h-SDA-2026-04-26-gap | GFAP-Bearing Circulating Extracellular Vesicles Originating from Reactive Astroc | 0.67 | 0.52 | GFAP (Glial Fibrillary Acidic Protein) on brain-derived EVs | proposed | 2026-04-26 | SDA-2026-04-26-gap-debate-20260426-011448-7c85f5dc |
| h-fa7ac9cb | Oligodendrocyte DNA Repair Enhancement Therapy | 0.66 | 0.55 | PARP1 and XRCC1 | proposed | 2026-04-04 | SDA-2026-04-03-gap-seaad-v2-20260402032945 |
| h-5a55aabc | Complement C1q Subtype Switching | 0.66 | 0.55 | C1QA | debated | 2026-04-02 | sda-2026-04-01-gap-005 |
| h-771680d84f53 | Labile iron pool expansion amplifies genotype-specific ALS ferroptosis | 0.66 | 0.64 | FTL | proposed | 2026-04-26 | SDA-2026-04-26-gap-ferroptosis-mnd-768eaeba1be3 |
| h-b662ff65 | Stathmin-2 Splice Switching to Prevent Axonal Degeneration Across the ALS-FTD-AD | 0.66 | 0.90 | STMN2 (stathmin-2), PTBP1/PTBP2 | promoted | 2026-04-13 | SDA-2026-04-13-gap-20260410-172514 |
| h-538dfc70 | TNF-α/IL-1β-Cx43 Hemichannel Axis as Upstream Link Between SASP and Synaptic Pru | 0.66 | 0.58 | TNF, IL1B → GJA1 → C1Q/C3 | proposed | 2026-04-13 | SDA-2026-04-12-gap-debate-20260410-113038-57244485 |
| h-5b0ebb1f | Choline Kinase Activity as Membrane Integrity Response Indicator | 0.66 | 0.30 | CHKA | proposed | 2026-04-17 | SDA-2026-04-04-gap-debate-20260403-222618-c698b06a |
| 32b2dd07-7c9a-416d-a | m6A Hypermethylation of SNCA mRNA Stabilises Alpha-Synuclein Transcript and Prom | 0.66 | 0.45 | SNCA | open | 2026-04-28 | b7f886d9-da3f-4e0d-a8a8-9c262e268796 |
| h-fffd1a74 | RNA Granule Nucleation Site Modulation | 0.66 | 0.70 | G3BP1 | debated | 2026-04-02 | sda-2026-04-01-gap-006 |
| h-6c06ca11ee | Vascular Cell Type Crosstalk Driving Blood-Brain Barrier Breakdown | 0.66 | 0.58 | MMP9 | proposed | 2026-04-28 | SDA-2026-04-28-gap-methodol-20260427-041425-9e73b245 |
| h-f78f8262 | Pericyte-First Sequential Biomarker Cascade — Soluble PDGFR-β as Sentinel Event | 0.66 | 0.18 | PDGFRB | proposed | 2026-04-26 | SDA-2026-04-26-gap-bbb-permeability-biomarker-20260426 |
| h-7f2d0e21 | Peripheral-Central Immune Decoupling Therapy | 0.66 | 0.59 | TREM2, complement cascade components | proposed | 2026-04-04 | SDA-2026-04-04-gap-neuroinflammation-microglial-20260404 |
| h-de52344d | Circadian-Metabolic Microglial Reprogramming | 0.66 | 0.59 | CLOCK, BMAL1, PER2 | proposed | 2026-04-04 | SDA-2026-04-04-gap-neuroinflammation-microglial-20260404 |
| h-20db7feba4 | Chronic cGAS/STING Hyperactivation Drives Progressive Neurodegeneration Through | 0.66 | 0.65 | cGAS (CGAS) / STING (TMEM173) / IFNAR1/2 | proposed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-062141-fc60e018 |
| h-d7212534 | Epigenetic Priming Ketone Protocol | 0.66 | 0.60 | HDAC2/HDAC3 | proposed | 2026-04-17 | SDA-BIOMNI-GENE_REG-785b71fe |
| h-737c3be8 | PARP1 Inhibition Blocks Poly(PR)-Triggered DNA Damage and Subsequent p53 Activat | 0.66 | 0.72 | PARP1 | promoted | 2026-04-15 | SDA-2026-04-15-gap-pubmed-20260411-090658-7651c1d2 |
| h_seaad_005 | Vascular mural cell degeneration precedes and exacerbates parenchymal pathology | 0.66 | 0.69 | PDGFRB | proposed | 2026-04-04 | SDA-2026-04-04-analysis_sea_ad_001 |
| h-49791706 | Biorhythmic Interference via Controlled Sleep Oscillations | 0.66 | 0.40 | GABRA1 | debated | 2026-04-02 | sda-2026-04-01-gap-009 |
| h-spark-b94e9126c05d | E2E direct hypothesis a980051375 | 0.66 | 0.50 | TREM2 | proposed | 2026-04-27 | |
| h-aa33c51749 | Clusterin (APOJ) Secretion Deficit | 0.66 | 0.65 | CLU (APOJ); VCP | proposed | 2026-04-26 | SDA-2026-04-26-gap-pubmed-20260410-170057-a2f72fd8-debate |
| h-immunity-03dc171e | SPP1+ DAM as Source of Autoimmunity in Neurodegeneration | 0.66 | 0.66 | SPP1, GALECTIN3, LGALS3, CXCR4 | open | 2026-04-24 | |
| h-ea85fbfb90 | Excitatory Neuron Synaptic Dysfunction and Mitochondrial Stress via MAPT (tau) | 0.66 | 0.75 | MAPT | proposed | 2026-04-22 | SDA-2026-04-02-gap-seaad-debate-v4 |
| h-8b0a41b274 | H6: miR-132/212 Cluster Silencing Disables Neuronal Chromatin Compaction and Sur | 0.66 | 0.71 | miR-132-3p, MeCP2, DNMT3A | proposed | 2026-04-22 | SDA-2026-04-04-gap-20260404-120802 |
| h-e8b3b9f971 | BBB Integrity Loss Defines Absolute Therapeutic Window Closure | 0.66 | 0.62 | MMP-9, Claudin-5, PDGFRβ (pericyte coverage) | proposed | 2026-04-22 | SDA-2026-04-06-gap-debate-20260406-062045-7a6cf14e |
| h-7619add3b8 | Axonal Transport Defect: C9orf72 hexanucleotide expansion impairs retrograde aut | 0.66 | 0.75 | C9orf72 | proposed | 2026-04-21 | SDA-2026-04-08-gap-pubmed-20260406-062212-6777e5dd |